Literature DB >> 9640215

Eight-year results of a prospective non-randomised study on therapy of small breast cancer. The German Breast Cancer Study Group (GBSG).

H F Rauschecker1, W Sauerbrei, W Gatzemeier, R Sauer, A Schauer, C Schmoor, M Schumacher.   

Abstract

In this report, the results of the first controlled clinical trial on breast cancer in Germany, begun in 1983, are presented after a median follow-up of 8 years. Four-year results have been previously published. In pT1 N0 M0 breast cancer, mastectomy as the standard treatment was to be compared with tumorectomy plus radiotherapy to the remaining breast tissue. The study design, originally planned as a comprehensive cohort study including randomised and non-randomised patients, had to be changed into a prospective observation study due to the low randomisation rate. 1036 out of 1119 recruited patients were evaluable. After a median follow-up of 97 months, 237 events (local recurrence, regional recurrence, distant metastases, contralateral breast cancer or death of the patient without previous recurrence) occurred. With the exception of death without recurrence, the events were evenly distributed among the two treatment groups. The 8-year local recurrence rate of the whole patient population is 8.8%. Out of all prognostic factors examined, only tumour size and grade had a significant influence on recurrent disease. Event-free survival decreased in cases with 'uncertain' tumour margins, whereas the width of the margin has no influence on disease recurrence. Based on 151 deaths observed so far, there was no significant difference in overall survival between the two treatment groups. The 8-year results of this study are in accordance with the 4-year results reported previously and with those of other breast-conserving treatment trials. There was no significant difference between the two treatment groups with regard to event-free and overall survival. Incomplete tumorectomy had a negative influence on recurrence.

Entities:  

Mesh:

Year:  1998        PMID: 9640215     DOI: 10.1016/s0959-8049(97)10035-1

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  6 in total

Review 1.  Meta-analytic comparison of randomized and nonrandomized studies of breast cancer surgery.

Authors:  Janet P Edwards; Elizabeth J Kelly; Yongtao Lin; Taryn Lenders; William A Ghali; Andrew J Graham
Journal:  Can J Surg       Date:  2012-06       Impact factor: 2.089

Review 2.  Systemic therapy for treating locoregional recurrence in women with breast cancer.

Authors:  H Rauschecker; M Clarke; W Gatzemeier; A Recht
Journal:  Cochrane Database Syst Rev       Date:  2001

3.  Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma.

Authors:  S Frkovic-Grazio; M Bracko
Journal:  J Clin Pathol       Date:  2002-02       Impact factor: 3.411

4.  Effectiveness of adjuvant radiotherapy in patients with oropharyngeal and floor of mouth squamous cell carcinoma and concomitant histological verification of singular ipsilateral cervical lymph node metastasis (pN1-state)--a prospective multicenter randomized controlled clinical trial using a comprehensive cohort design.

Authors:  Maximilian Moergel; Antje Jahn-Eimermacher; Frank Krummenauer; Torsten E Reichert; Wilfried Wagner; Thomas G Wendt; Jochen A Werner; Bilal Al-Nawas
Journal:  Trials       Date:  2009-12-23       Impact factor: 2.279

5.  The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis.

Authors:  Nehmat Houssami; Petra Macaskill; M Luke Marinovich; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2014-01-29       Impact factor: 5.344

6.  Synchronous and metachronous breast malignancies: a cross-sectional retrospective study and review of the literature.

Authors:  Ambrogio P Londero; Sergio Bernardi; Serena Bertozzi; Vito Angione; Giuliana Gentile; Cinzia Dri; Antonio Minucci; Filippo Caponnetto; Roberto Petri
Journal:  Biomed Res Int       Date:  2014-04-27       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.